Why did Centene Corporation (CNC) stock move recently?

On 7/23/2026, Centene Corporation moved -3.3% — Centene shares fell with the broader market or healthcare sector, as no company-specific news, earnings, or filing was released today ahead of the scheduled Q2 report on July 28. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Centene Corporation (CNC) overvalued or fairly valued?

MarketChacha shows Centene Corporation's valuation in context — a forward P/E of about 12.1, a price-to-book of about 1.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Centene Corporation's revenue?

Centene Corporation reported revenue of $174.6B for FY2025, with net profit of $-6.7B, per official filings.

What is the share price of Centene Corporation (CNC)?

Centene Corporation last traded at $65.22 (+1.3% on the day), as of 8/18/2026 — a delayed quote shown for education, not investment advice.

Centene Corporation

CNC · NYSE · Healthcare · United States

Snapshot

TickerCNC

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

Employees61,100

HeadquartersSaint Louis, United States

Websitewww.centene.com

Filings tracked20

About Centene Corporation

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

Who owns it

Insiders0.4%
Institutions99.6%
Public & other0.0%

1,398 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.39%
Vanguard Capital Management LLC6.37%
AQR Capital Management, LLC5.81%
Vanguard Portfolio Management LLC4.52%
State Street Corporation4.45%
Geode Capital Management, LLC2.69%
Wellington Management Group, LLP2.69%
Ameriprise Financial, Inc.2.51%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 5.8 points over the period — profitability is trending down.

Net margin trend1.9% → -3.8%

Margin has compressed by about 5.8 points over the period — profitability is trending down.

Return on equity-33.4%

Latest ROE of -33.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $45.4B · EPS -1.09

Est. earnings growth +8.4%

Next fiscal year

Rev $193.6B · EPS 5.32

Est. earnings growth +8.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$174.6B

Net margin

-3.8%

ROE

-33.4%

Revenue CAGR (2y)

+11.6%

EPS (FY2025)

-13.53

Net profit (FY2025)

$-6.7B

Ask MarketChacha about CNC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 23, 2026
Centene shares fell with the broader market or healthcare sector, as no company-specific news, earnings, or filing was released today ahead of the scheduled Q2 report on July 28.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$174.6B	$-6.7B	-13.53	-3.8%	-33.4%
FY2024	$145.5B	$3.3B	6.31	2.3%	12.5%
FY2023	$140.1B	$2.7B	4.95	1.9%	10.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$44.4B	$1.1B	2.19	2.5%
2026Q1	$44.7B	$1.5B	3.11	3.5%
2025Q3	$44.9B	$-6.6B	-13.50	-14.8%
2025Q2	$42.5B	$-253.0M	-0.51	-0.6%
2025Q1	$42.5B	$1.3B	2.63	3.1%
2024Q3	$36.9B	$713.0M	1.36	1.9%
2024Q2	$36.0B	$1.1B	2.16	3.2%
2024Q1	$36.3B	$1.2B	2.16	3.2%
2023Q3	$35.0B	$469.0M	0.87	1.3%
2023Q2	$34.8B	$1.1B	1.92	3.0%
2023Q1	$35.0B	$1.1B	2.04	3.2%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events
SEC7/29/2026material
10-Q filing
SEC7/28/2026
8-K — Results of operations, Executive/director change, Reg FD disclosure, Exhibits
SEC7/28/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/22/2026material
8-K — Executive/director change, Shareholder vote results
SEC5/15/2026material
10-Q filing
SEC4/28/2026
8-K — Results of operations, Exhibits
SEC4/28/2026material
8-K — Executive/director change
SEC3/24/2026material
8-K — Reg FD disclosure, Other events
SEC3/10/2026material
8-K — Reg FD disclosure
SEC2/23/2026material
10-K filing
SEC2/17/2026
8-K — Results of operations, Exhibits
SEC2/6/2026material

2025

8-K — Reg FD disclosure
SEC11/10/2025material
10-Q filing
SEC10/29/2025
8-K — Results of operations, Exhibits
SEC10/29/2025material
8-K — Reg FD disclosure
SEC9/11/2025material
8-K — Executive/director change
SEC8/15/2025material
8-K — Executive/director change
SEC8/4/2025material
10-Q filing
SEC7/25/2025
8-K — Results of operations, Exhibits
SEC7/25/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.